PMGC Holdings (ELAB)
NASDAQ:ELAB
Top Page
PMGC Holdings
(NASDAQ:ELAB)
Select Model
Select Model
Rating:45Neutral
Price Target:
$4.50
â–²(190.32% Upside)
Action:ReiteratedDate:04/10/26
The score is held down primarily by weak financial performance (volatile revenue, large operating losses, and sustained cash burn). Technicals also remain bearish (below key moving averages with negative MACD). Corporate events provide some offset via strategic expansion and contracts/compliance wins, but financing-related risk and the lack of profitability keep the overall score low.
Positive Factors
Defense supply contracts
The multi-year Tier 1 supply agreement formalizes recurring demand for mission-critical components, giving AGA predictable revenue and operational visibility. Over 2-6 months this strengthens backlog, supports stable factory utilization, and raises barriers versus one-off suppliers.
Negative Factors
Persistent cash burn
Sustained negative operating and free cash flow forces repeated external funding and limits reinvestment. Over months this elevates liquidity and runway risk, constrains ability to scale operations or commercialize tech, and increases likelihood of dilutive financing under stressed conditions.
Read all positive and negative factors
Positive Factors
Negative Factors
Defense supply contracts
The multi-year Tier 1 supply agreement formalizes recurring demand for mission-critical components, giving AGA predictable revenue and operational visibility. Over 2-6 months this strengthens backlog, supports stable factory utilization, and raises barriers versus one-off suppliers.
Read all positive factors
PMGC Holdings (ELAB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$10.19M
Dividend YieldN/A
Average Volume (3M)89.87K
Price to Earnings (P/E)―
Beta (1Y)3.14
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees2
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,936,771
10 Day Avg. Volume35,159
30 Day Avg. Volume89,868
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.37
Price to Sales (P/S)4.90
P/FCF Ratio-0.45
Enterprise Value/Market Cap0.64
Enterprise Value/Revenue11.05
Enterprise Value/Gross Profit87.15
Enterprise Value/Ebitda-0.90
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PMGC Holdings Business Overview & Revenue Model
Company Description
PMGC Holdings Inc., a biopharmaceutical company, focuses on the development and acquisition of cutting-edge aesthetic medicines and therapeutic products. The company's lead product includes EL-22, a first-in-class engineered probiotic approach to ...
How the Company Makes Money
null...
PMGC Holdings Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
54
Neutral
Cash Flow
14
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 590.08K | 2.47M | 1.71M | 766.28K | 827.00 |
| Gross Profit | 74.81K | 1.80M | 1.13M | 447.31K | -2.02K |
| EBITDA | -7.27M | -3.20M | -4.27M | -1.79M | -782.30K |
| Net Income | -7.71M | -6.25M | -4.30M | -1.80M | -784.74K |
Balance Sheet | |||||
| Total Assets | 12.87M | 8.99M | 5.19M | 1.89M | 666.25K |
| Cash, Cash Equivalents and Short-Term Investments | 5.40M | 3.98M | 3.33M | 1.15M | 411.86K |
| Total Debt | 2.64M | 0.00 | 210.49K | 283.22K | 0.00 |
| Total Liabilities | 5.03M | 2.33M | 1.36M | 760.87K | 215.62K |
| Stockholders Equity | 7.84M | 6.66M | 3.83M | 1.13M | 450.63K |
Cash Flow | |||||
| Free Cash Flow | -6.38M | -5.49M | -4.57M | -1.62M | -693.42K |
| Operating Cash Flow | -5.93M | -5.49M | -4.56M | -1.59M | -660.93K |
| Investing Cash Flow | -2.77M | -610.56K | -11.19K | -32.03K | -32.48K |
| Financing Cash Flow | 10.12M | 6.76M | 6.74M | 2.36M | 1.09M |
PMGC Holdings Technical Analysis
Neutral
1.55
Price Trends
7.40
Negative
38.87
Negative
97.93
Negative
Market Momentum
-0.93
Negative
48.24
Neutral
22.48
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ELAB, the sentiment is Neutral. The current price of 1.55 is below the 20-day moving average (MA) of 4.41, below the 50-day MA of 7.40, and below the 200-day MA of 97.93, indicating a neutral trend. The MACD of -0.93 indicates Negative momentum. The RSI at 48.24 is Neutral, neither overbought nor oversold. The STOCH value of 22.48 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ELAB.
PMGC Holdings Risk Analysis
PMGC Holdings disclosed 79 risk factors in its most recent earnings report. PMGC Holdings reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
PMGC Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $10.19M | -0.38 | -82.41% | ― | ― | ― | |
43 Neutral | $1.47M | -0.07 | -63.03% | ― | -100.00% | 86.75% | |
42 Neutral | $4.15M | -0.13 | -317.98% | ― | ― | 34.57% | |
42 Neutral | $1.88M | ― | -82.17% | ― | -3.27% | 51.83% | |
42 Neutral | $1.73M | -0.15 | -197.11% | ― | ― | 99.87% |
* Healthcare Sector Average
ELAB
PMGC Holdings
5.26
-252.62
-97.96%
BDRX
Biodexa Pharmaceuticals
3.25
-85.25
-96.33%
INDP
Indaptus Therapeutics
1.85
-11.59
-86.24%
INM
InMed Pharmaceuticals
0.64
-2.10
-76.53%
CNSP
CNS Pharmaceuticals
2.13
-13.95
-86.75%
PMGC Holdings Corporate Events
Business Operations and Strategy
PMGC Holdings Expands Aerospace Defense Supply Agreements Portfolio
Positive
Apr 9, 2026
On April 9, 2026, AGA Precision Systems LLC, a precision CNC aerospace and defense manufacturer owned by PMGC Holdings Inc., signed a second long-term supply agreement with a globally recognized Tier 1 aerospace and defense company, after a prior ...
Business Operations and StrategyM&A TransactionsPrivate Placements and Financing
PMGC Utilizes Equity Facility to Fund Acquisition Strategy
Positive
Apr 8, 2026
On April 8, 2026, PMGC Holdings said it had fully utilized the $20 million commitment under its equity purchase facility with Streeterville Capital, reinforcing its cash position to fund a near-term acquisition pipeline and integration efforts. Ma...
Business Operations and StrategyProduct-Related Announcements
PMGC Explores Advanced Dual-Domain Drone Logistics Technology
Positive
Apr 6, 2026
On April 6, 2026, NorthStrive Defense Tech LLC, a wholly owned subsidiary of PMGC Holdings Inc., announced it had secured an exclusive option to license U.S. Patent No. 12,291,334, a next‑generation drone system that transports cable‑s...
Business Operations and Strategy
PMGC Launches NorthStrive Subsidiary Targeting Defense Technology Growth
Positive
Apr 2, 2026
On April 2, 2026, PMGC Holdings Inc. launched NorthStrive Defense Tech LLC, a wholly owned subsidiary created to target the high-growth defense technology market, with a focus on drones, autonomous systems and next-generation unmanned defense solu...
Business Operations and Strategy
PMGC Holdings Updates Northstrive Licensing Milestones with MOA
Neutral
Mar 27, 2026
On March 24, 2026, Northstrive Biosciences Inc., a subsidiary of PMGC Holdings Inc., executed a third amendment to its license agreement with Korea’s MOA Life Plus Co., Ltd., originally signed on April 30, 2024. The amendment replaces the pr...
Business Operations and StrategyRegulatory Filings and Compliance
PMGC Holdings Subsidiary Gains ITAR Defense Compliance Status
Positive
Mar 24, 2026
On March 24, 2026, PMGC Holdings said its subsidiary SVM Machining, Inc. has completed registration under the International Traffic in Arms Regulations, confirming compliance with U.S. export-control rules for defense articles and services. The IT...
Business Operations and StrategyExecutive/Board ChangesRegulatory Filings and Compliance
PMGC Holdings Updates Executive Consulting Fee Agreements
Neutral
Mar 23, 2026
On March 17, 2026, PMGC Holdings Inc. amended its consulting agreement with GB Capital Ltd., the entity wholly owned by CEO, CFO, and director Graydon Bensler, setting GB Capital’s annual consulting fee at $300,000 and confirming that this l...
Business Operations and StrategyStock Split
PMGC Holdings Announces 1-for-6 Reverse Stock Split
Neutral
Mar 10, 2026
PMGC Holdings Inc. said on March 4, 2026, that it will implement a 1-for-6 reverse stock split of its common stock, effective March 10, 2026, consolidating every six issued, outstanding and authorized shares into one share and assigning a new CUSI...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
PMGC Holdings Enters Fourth Secured Pre-Paid Equity Deal
Negative
Mar 3, 2026
On February 6, 2026, PMGC Holdings completed a fourth secured pre-paid equity purchase with an institutional investor, carrying an original principal of about $8.15 million and net proceeds of roughly $7.46 million, largely deposited into a contro...
Business Operations and StrategyProduct-Related Announcements
PMGC Expands EL-22, EL-32 Tech Into Animal Health
Positive
Feb 19, 2026
On February 18, 2026, NorthStrive Biosciences, a subsidiary of PMGC Holdings, filed ten new U.S. patent applications to extend its EL-22 and EL-32 technologies into animal health and agricultural markets across livestock, aquaculture and poultry. ...
Business Operations and StrategyProduct-Related Announcements
PMGC Subsidiary Licenses Animal Health Rights to Modulant
Positive
Feb 11, 2026
On February 11, 2026, Northstrive Biosciences, a subsidiary of PMGC Holdings, announced it had signed a definitive, exclusive worldwide license agreement with Modulant Biosciences for EL-22 and EL-32 in non-human animal health, excluding South Kor...
Business Operations and StrategyM&A Transactions
PMGC Holdings Completes Acquisition of SVM Machining
Positive
Feb 6, 2026
On February 2, 2026, PMGC Holdings Inc. completed the acquisition of 100% of SVM Machining, Inc., a California-based ISO 9001:2015 certified CNC precision machining company that supplies custom, high-tolerance components to medical, aerospace, bio...
Private Placements and Financing
PMGC Holdings Secures Third Structured Pre-Paid Equity Facility
Neutral
Jan 20, 2026
On January 13, 2026, PMGC Holdings completed its third secured pre-paid equity purchase with an institutional investor under an existing securities purchase agreement, establishing a $5,464,500 principal pre-paid facility with a $464,500 original ...
Private Placements and Financing
PMGC Holdings Closes Second Secured Pre-Paid Equity Deal
Neutral
Jan 12, 2026
On January 7, 2026, PMGC Holdings entered into and closed a second secured pre-paid equity purchase with an existing investor under its previously established equity purchase facility, raising $3 million in gross proceeds and approximately $2.73 m...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.